| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 05/19/2011 | CA2780761A1 Factor viii t cell epitope variants having reduced immunogenicity |
| 05/19/2011 | CA2780740A1 The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease |
| 05/19/2011 | CA2780583A1 Protein concentrates and isolates, and processes for the production thereof |
| 05/19/2011 | CA2780579A1 Protein concentrates and isolates, and processes for the production thereof from toasted oilseed meal |
| 05/19/2011 | CA2780572A1 Modulated programmed death ligand-1 |
| 05/19/2011 | CA2780529A1 Use of a protein homologous to an meab protein for increasing the enzymatic activity of a 3-hydroxycarboxylic acid-coa mutase |
| 05/19/2011 | CA2780208A1 Therapeutic and diagnostic applications against trypanosomosis |
| 05/19/2011 | CA2780142A1 Compounds and methods for purifying peptides produced by solid phase peptide synthesis |
| 05/19/2011 | CA2779988A1 Plants having enhanced yield-related traits and a method for making the same |
| 05/19/2011 | CA2779293A1 Solution assay and high through-put screen to probe interaction between human cullin-ring ligase complex and hiv-vif protein |
| 05/19/2011 | CA2779290A1 Ligand-targeted multi-stereoisomer peptide polymer conjugates and uses thereof |
| 05/19/2011 | CA2778809A1 Antibody glycosylation variants |
| 05/19/2011 | CA2775373A1 Antibodies specific for claudin 6 (cldn6) |
| 05/18/2011 | EP2322933A1 Diagnosis of carcinomas |
| 05/18/2011 | EP2322929A1 Diagnostics, drug screening and treatment for cancer |
| 05/18/2011 | EP2322668A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms. |
| 05/18/2011 | EP2322667A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms. |
| 05/18/2011 | EP2322666A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms. |
| 05/18/2011 | EP2322637A1 Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5AR |
| 05/18/2011 | EP2322635A2 Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof |
| 05/18/2011 | EP2322634A2 Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof |
| 05/18/2011 | EP2322633A2 Preparation of organisms with faster growth and/or higher yield |
| 05/18/2011 | EP2322631A1 In vivo incorporation of unnatural amino acids |
| 05/18/2011 | EP2322628A2 Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 |
| 05/18/2011 | EP2322627A2 Mutations in the BCR-abl tyrosine kinase associated with resistance to STI-571 |
| 05/18/2011 | EP2322626A1 HIV-GAG codon-optimised DNA vaccines |
| 05/18/2011 | EP2322625A1 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof |
| 05/18/2011 | EP2322620A2 Analogs of human pancreatic polypeptide and their effects on feeding behaviour |
| 05/18/2011 | EP2322619A1 Inhibitors of centrosomal clustering |
| 05/18/2011 | EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy |
| 05/18/2011 | EP2322609A1 Hcv/gbv-b chimeric virus |
| 05/18/2011 | EP2322605A2 Terpene synthases |
| 05/18/2011 | EP2322604A1 Technique for regulating regeneration of tissue or faulty or abnormal part in organ using nell-1 |
| 05/18/2011 | EP2322603A1 Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| 05/18/2011 | EP2322572A1 Gluten biopolymers |
| 05/18/2011 | EP2322558A1 Antibodies directed against glycoprotein VI and uses thereof |
| 05/18/2011 | EP2322555A1 Antibodies specific for claudin 6 (CLDN6) |
| 05/18/2011 | EP2322553A2 Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| 05/18/2011 | EP2322548A1 NPC1L1 (NPC) and methods of use thereof |
| 05/18/2011 | EP2322547A1 Myeloid cell-specific lectin |
| 05/18/2011 | EP2322546A1 Acylated GLP-1 compounds |
| 05/18/2011 | EP2322545A1 Analogues of GLP-1 |
| 05/18/2011 | EP2322544A2 Differential in tumour gene products and use of same |
| 05/18/2011 | EP2322543A1 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm |
| 05/18/2011 | EP2322542A1 Reproductive ablation constructs |
| 05/18/2011 | EP2322541A1 Gq protein competitive inhibitory polypeptides, preparation methods and uses thereof |
| 05/18/2011 | EP2322540A1 Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof |
| 05/18/2011 | EP2322539A2 A method for identification, isolation and production of antigens to a specific pathogen |
| 05/18/2011 | EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 05/18/2011 | EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof |
| 05/18/2011 | EP2322207A2 Oxygen-transferring blood substitute and a pharmaceutical composition (variants) |
| 05/18/2011 | EP2322206A2 Mutated netrin 1, fragments thereof and uses thereof as drugs |
| 05/18/2011 | EP2322205A1 Polymer-conjugated glycosylated neublastin |
| 05/18/2011 | EP2322203A2 Compositions and methods for the treatment of immune related diseases |
| 05/18/2011 | EP2322202A2 Compositions and methods for the treatment of immune diseases |
| 05/18/2011 | EP2322201A2 Compositions and methods for the treatment of immune related diseases |
| 05/18/2011 | EP2322200A2 Compositions and methods for the treatment of immune related diseases |
| 05/18/2011 | EP2322199A1 Growth differentiation factor receptors, and methods of using same |
| 05/18/2011 | EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 05/18/2011 | EP2322147A1 Use of microparticles containing genetically modified cells in the treatment of neurodegenerative diseases |
| 05/18/2011 | EP2321351A2 Antibodies to ccr2 |
| 05/18/2011 | EP2321346A1 Methods and substances for stimulating muscle regeneration |
| 05/18/2011 | EP2321345A1 Multi-specific binding proteins targeting b cell disorders |
| 05/18/2011 | EP2321344A2 New insulin analogues of prolonged activity |
| 05/18/2011 | EP2321343A2 Novel retinoid inducible factor and uses thereof |
| 05/18/2011 | EP2321342A2 Combination therapy of hiv fusion/entry inhibitors targeting gp41 |
| 05/18/2011 | EP2321340A1 Novel melanoma antigen peptide and uses thereof |
| 05/18/2011 | EP2320946A1 Allergoids derived from allergenes |
| 05/18/2011 | EP2320932A2 Methods of predicting cancer lethality using replikin counts |
| 05/18/2011 | EP2320931A2 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |
| 05/18/2011 | EP2320747A1 Preparation of canola protein isolate from canola oil seeds ("blendertein") |
| 05/18/2011 | EP2320746A1 Soluble canola protein isolate production from protein micellar mass |
| 05/18/2011 | EP2121742B1 Metastasis-specific peptides and their diagnostic and therapeutic applications |
| 05/18/2011 | EP2046821B1 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins |
| 05/18/2011 | EP2041181B1 Specific protease inhibitors and their use in cancer therapy |
| 05/18/2011 | EP2041161B1 Chiral compounds substituted with phosphonate ester or phosphonic acid |
| 05/18/2011 | EP1809661B1 Human interferon-beta mutein |
| 05/18/2011 | EP1799715B1 Thyrotropin receptor preparations, binding regions thereof, antibody and hormone interactions therewith, and uses thereof |
| 05/18/2011 | EP1797120B1 Deglycosylated and desialidated long pentraxin ptx3 |
| 05/18/2011 | EP1766011B1 Methods and uses of polypeptide ligands containing linkers |
| 05/18/2011 | EP1701611B1 Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| 05/18/2011 | EP1575867B1 Peptide nanostructures, methods for their preparation and use |
| 05/18/2011 | EP1565559B1 Fluorescent proteins and chromoproteins from non-aequorea hydrozoa species and methods for using same |
| 05/18/2011 | EP1494541B1 Canola protein isolate compositions |
| 05/18/2011 | EP1451325B1 Transcription factor stress-related polypeptides and methods of use in plants |
| 05/18/2011 | EP1366168B1 Plant-derived molecules and genetic sequences encoding same and uses therefor |
| 05/18/2011 | EP1305422B1 2,5-dkg permeases |
| 05/18/2011 | EP1238089B1 Synthetic human genes and polypeptides and their use in the treatment of autoimmune diseases |
| 05/18/2011 | EP1032595B1 Nucleic acids involved in the responder phenotype and applications thereof |
| 05/18/2011 | CN1425068B Fungal transcriptional activator useful in methods for producing polypeptides |
| 05/18/2011 | CN1377415B 疫苗组合物 Vaccine compositions |
| 05/18/2011 | CN102066945A Modulators of STAT3 signalling |
| 05/18/2011 | CN102066938A Method for determination of edema associated with liver disease |
| 05/18/2011 | CN102066569A Plants having enhanced yield-related traits and a method for making the same |
| 05/18/2011 | CN102066422A Lysosomal targeting peptides and uses thereof |
| 05/18/2011 | CN102066421A Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-MSK) and atrial natriuretic protein (ANP) and uses in hypertension and acute kidney injury |
| 05/18/2011 | CN102066417A A process of purifying coagulation factor VIII |
| 05/18/2011 | CN102066416A Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 05/18/2011 | CN102066415A Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof |
| 05/18/2011 | CN102066414A Recombinant FSH including alpha2,3- and alpha2,6-sialylation |